Oncotelic Therapeutics, Inc. (OTCQB: OTLC) announced the completion of key Phase 2 objectives in its manufacturing automation initiative with TechForce Robotics, advancing the commercialization of an AI-powered good manufacturing practices (GMP) manufacturing services platform at SAPU Bio, the company's 45%-owned sterile injectable cGMP manufacturing joint venture. This development marks a significant step toward integrating artificial intelligence into pharmaceutical production, with potential implications for cost reduction, quality control, and scalability.
The Phase 2 deployment expands the capabilities of Oncotelic's proprietary PDAOAI platform across sterile manufacturing operations, electronic batch records, GMP workflow execution, cleanroom monitoring and autonomous materials movement. By combining PDAOAI with TechForce's autonomous robotic systems, the integrated platform supports intelligent pharmaceutical manufacturing and creates potential opportunities in software licensing, automation deployment, manufacturing partnerships and technology-enabled contract development and manufacturing services (CDMO). The company plans to demonstrate the platform at the BIO International Convention 2026 in San Diego as it pursues broader commercialization efforts within the pharmaceutical manufacturing sector.
Oncotelic Therapeutics is a clinical-stage biopharmaceutical company focused on oncology and immunotherapy products, addressing high-unmet-need cancers and rare pediatric indications. Beyond its internal pipeline, the company leverages its proprietary AI-enabled PDAOAI platform, which supports research, biomarker discovery, and regulatory processes through advanced data analysis and knowledge integration. The company also licenses and co-develops select drug candidates through strategic partnerships and joint ventures, including its 45% interest in GMP Bio.
This announcement is important because it signals a shift toward AI-driven automation in pharmaceutical manufacturing, an area where efficiency and precision are critical. The successful completion of Phase 2 objectives suggests that Oncotelic's platform could reduce human error, accelerate production timelines, and lower costs—benefits that may ultimately translate into more affordable and reliable drug supply. For a company already involved in oncology and rare disease therapeutics, this technology could enhance its competitive edge and open new revenue streams through licensing and CDMO services.
Investors should note that the company's news and updates are available in its newsroom at https://nnw.fm/OTLC. The full press release can be accessed at https://nnw.fm/j1n43.
